Bruce Lehman Elected to Matritech Board of Directors; Co-founder and CEO of LehmanMillet, Leading Diagnostic and Device Agency

Business Wire,  June 13, 2006  

• E-mail
• Print
• Link

NEWTON, Mass. -- Bruce Lehman was elected to Matritech's (Amex: MZT) Board of Directors at the company's annual meeting, held on June 9, 2006. Mr. Lehman, co-founder and CEO of LehmanMillet, Incorporated, the leading integrated marketing services firm providing support to the medical device and diagnostics industry, is an industry veteran with over 30 years experience. During his 28 years at LehmanMillet, headquartered in Boston with offices in California and the U.K., Mr. Lehman established one of the industry's most respected agencies focused on the commercialization of medical devices and diagnostics, driving marketplace acceptance of these emerging technologies. In 2002 LehmanMillet joined HealthStar Communications, a healthcare marketing services network.

"Bruce's industry-wide experience and strategic insights are an important addition to our Board of Directors. As we continue to grow and expand our NMP22(R) BladderChek(R) Test franchise and develop our product pipeline, his strategic counsel will be an integral part of our commercial plans," commented Stephen D. Chubb, Chairman and CEO. "We welcome Bruce; it is a privilege to be associated with someone of his reputation and accomplishments."

Extending his expertise to the medical marketing community, Mr. Lehman has been a member of the Biomedical Marketing Association since 1982, a member of its Board of Directors since 1996, President in 2004-2005, and currently serves as Immediate Past President. He was invited to join the Harvard-MIT Division of Health Sciences and Technology (HST) Advisory Council in 2001 and has served on the HST Advisory Board since 2003. In addition, he is a charter member of MassMEDIC, an organization dedicated to the Medical Device Industry in Massachusetts, and served on its founding Board of Directors from 1997 to 2000. Mr. Lehman is a past member of the Board of Directors of the Medical Marketing Association (MMA) and the American Association of Advertising Agencies (AAAA). He is a current member of both organizations. Celebrated for his cogent observations and inventive explanations, Mr. Lehman is widely sought as a commentator on the marketing of medical devices and diagnostics.

Born in Rhode Island, and raised as the son of a military family, Mr. Lehman graduated summa cum laude from Rutgers University in 1971. From 1971 through 1973, he was a partner in a privately held, wooden novelty manufacturing firm. From 1973 until he co-founded LehmanMillet in December of 1978, he was an independent corporate speechwriter, specializing in board of director, strategic plan, shareholder meeting and business plan presentations for senior executives of Fortune 500 companies including Corning, Inc., IBM, Bausch&Lomb, and Kodak.

About Matritech

Matritech is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company's first two products, the NMP22(R) Test Kit and NMP22(R) BladderChek(R) Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22 BladderChek Test is based on Matritech's proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech's patent portfolio has grown to more than 15 other U.S. patents. In addition to the NMP22 protein marker utilized in the NMP22 Test Kit and NMP22 BladderChek Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company's goal is to utilize these protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com.

Statement under the Private Securities Litigation Reform Act

Any forward-looking statements relate to the Company's current expectations of the Company's products and technology. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Company's business, including without limitation risks and uncertainties including those detailed in the Company's periodic reports and registration statements as filed with the Securities and Exchange Commission. These forward-looking statements are neither promises nor guarantees. There can be no assurance that the Company's expectations for its products will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Matritech undertakes no responsibility to revise or update any such forward-looking information.

COPYRIGHT 2006 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning